Vertex Pharmaceuticals Inc (VRTX) stock
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3030% above fair value
$534.20−3.59 (-0.67%)
Close on Nov 17, 2026Market cap $135.40BP/E 31.1Yield –
Vertex Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Vertex Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was $4.78B, up 21.8% year over year. For fiscal 2025 it was $4.17B. The highest annual figure on record is $4.31B in fiscal 2022.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.17B | – |
| FY2024 | Dec 31, 2024 | -$232.90M | -106.1% |
| FY2023 | Dec 31, 2023 | $3.83B | -11.0% |
| FY2022 | Dec 31, 2022 | $4.31B | +54.8% |
| FY2021 | Dec 31, 2021 | $2.78B | -2.6% |
| FY2020 | Dec 31, 2020 | $2.86B | +138.5% |
| FY2019 | Dec 31, 2019 | $1.20B | +88.5% |
| FY2018 | Dec 31, 2018 | $635.15M | +415.4% |
| FY2017 | Dec 31, 2017 | $123.24M | +1140.4% |
| FY2016 | Dec 31, 2016 | $9.94M | – |
| FY2015 | Dec 31, 2015 | -$466.88M | – |
| FY2014 | Dec 31, 2014 | -$692.41M | – |
| FY2013 | Dec 31, 2013 | -$610.01M | -1405.5% |
| FY2012 | Dec 31, 2012 | $46.73M | -58.9% |
| FY2011 | Dec 31, 2011 | $113.82M | – |
| FY2010 | Dec 31, 2010 | -$696.08M | – |
| FY2009 | Dec 31, 2009 | -$614.01M | – |
| FY2008 | Dec 31, 2008 | -$462.71M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.25B | +8.3% |
| Q1 FY2026 | Mar 31, 2026 | $1.14B | +80.6% |
| Q4 FY2025 | Dec 31, 2025 | $1.21B | +17.5% |
| Q3 FY2025 | Sep 30, 2025 | $1.19B | +6.3% |
| Q2 FY2025 | Jun 30, 2025 | $1.15B | – |
| Q1 FY2025 | Mar 31, 2025 | $630.10M | -44.7% |
| Q4 FY2024 | Dec 31, 2024 | $1.03B | +3.8% |
| Q3 FY2024 | Sep 30, 2024 | $1.12B | +7.5% |
| Q2 FY2024 | Jun 30, 2024 | -$3.51B | -442.4% |
| Q1 FY2024 | Mar 31, 2024 | $1.14B | +46.3% |
| Q4 FY2023 | Dec 31, 2023 | $988.50M | -4.4% |
| Q3 FY2023 | Sep 30, 2023 | $1.04B | -7.9% |
| Q2 FY2023 | Jun 30, 2023 | $1.03B | -7.2% |
| Q1 FY2023 | Mar 31, 2023 | $779.00M | -25.2% |
| Q4 FY2022 | Dec 31, 2022 | $1.03B | +17.8% |
| Q3 FY2022 | Sep 30, 2022 | $1.13B | +6.8% |
| Q2 FY2022 | Jun 30, 2022 | $1.11B | – |
| Q1 FY2022 | Mar 31, 2022 | $1.04B | +17.2% |
| Q4 FY2021 | Dec 31, 2021 | $877.70M | +17.7% |
| Q3 FY2021 | Sep 30, 2021 | $1.05B | +56.9% |
| Q2 FY2021 | Jun 30, 2021 | -$37.90M | -105.3% |
| Q1 FY2021 | Mar 31, 2021 | $887.80M | +23.3% |
| Q4 FY2020 | Dec 31, 2020 | $745.79M | +35.2% |
| Q3 FY2020 | Sep 30, 2020 | $672.24M | +576.8% |
| Q2 FY2020 | Jun 30, 2020 | $718.03M | +166.0% |
| Q1 FY2020 | Mar 31, 2020 | $720.22M | +160.2% |
| Q4 FY2019 | Dec 31, 2019 | $551.47M | +331.8% |
| Q3 FY2019 | Sep 30, 2019 | $99.33M | -51.7% |
| Q2 FY2019 | Jun 30, 2019 | $269.96M | +56.2% |
| Q1 FY2019 | Mar 31, 2019 | $276.81M | +114.7% |
| Q4 FY2018 | Dec 31, 2018 | $127.72M | +1.6% |
| Q3 FY2018 | Sep 30, 2018 | $205.65M | – |
| Q2 FY2018 | Jun 30, 2018 | $172.88M | +228.0% |
| Q1 FY2018 | Mar 31, 2018 | $128.90M | -52.4% |
| Q4 FY2017 | Dec 31, 2017 | $125.74M | +217.2% |
| Q3 FY2017 | Sep 30, 2017 | -$326.04M | – |
| Q2 FY2017 | Jun 30, 2017 | $52.71M | – |
| Q1 FY2017 | Mar 31, 2017 | $270.84M | – |
| Q4 FY2016 | Dec 31, 2016 | $39.64M | – |
| Q3 FY2016 | Sep 30, 2016 | -$18.73M | – |
See a number that looks wrong?